Drug
TGFB3 protein, human clinical trials
Also written Avotermin, Juvista and RN1001.
How studies write it
Studies that test it under each name
Brand
- Juvista
- 10
Other names
Studies by the year they started
18 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 2 |
| 2006 | 4 |
| 2008 | 2 |
| 2009 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Cicatrix
- 14
Who runs them
Industry 18 · Other 0
Studies
Open first, then newest update. How each study uses TGFB3 protein, human is read from its arms, and is right about nine times in ten.
Testing it · 18
- Juvista in Scar Revision Surgery of Disfiguring ScarsCompletedPhase 3RenovoNCT00742443Written as Juvista (avotermin)
- A Trial to Compare the Efficacy of Two Formulations of Avotermin Against PlaceboCompletedPhase 1RenovoNCT01029158Written as Juvista (Avotermin)
- Juvista (Avotermin) in Scars Following Varicose Vein RemovalCompletedPhase 2RenovoNCT00430326Written as Avotermin
- Safety of Juvista When Administered Following Excision of Ear Lobe KeloidsCompletedPhase 1/2RenovoNCT00710333Written as Avotermin
- Juvista in the Non-surgical Improvement of Existing ScarsWithdrawnNot applicableRenovoNCT00821457Written as Juvista
- Safety and Efficacy Study of Avotermin (Juvista) in Female SubjectsCompletedPhase 1/2RenovoNCT00984581Written as Avotermin
- Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor SitesCompletedPhase 2RenovoNCT00984503Written as Avotermin
- Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)CompletedPhase 1/2RenovoNCT00978367Written as Avotermin
- Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)CompletedPhase 1RenovoNCT00978302Written as Avotermin
- Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male SubjectsCompletedPhase 1/2RenovoNCT00977951Written as Intradermal avotermin
- Safety and Efficacy of RN1001(Avotermin) in Healthy Male SubjectsCompletedPhase 1/2RenovoNCT00847925Written as Avotermin (RN1001)
- Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.CompletedPhase 1/2RenovoNCT00847795Written as Avotermin
- Juvista (Avotermin) in Breast Reduction Surgery ScarsTerminatedPhase 2RenovoNCT00432328Written as Avotermin
- RN1001(Avotermin) in Scar Improvement Following Breast AugmentationCompletedPhase 2RenovoNCT00436449Written as Avotermin
- A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi ExcisionStatus unknownPhase 2RenovoNCT00656227Written as Avotermin
- Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and WomenCompletedPhase 2RenovoNCT00629811Written as Avotermin (Juvista)
- Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin IncisionsCompletedPhase 2RenovoNCT00627536Written as Avotermin
- Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy MalesCompletedPhase 2RenovoNCT00594581Written as Juvista (avotermin) plus placebo, standard-care (within-subject controls)
Codes
What other systems call TGFB3 protein, human · ClinicalTrials.gg INT004887
- MeSH (NLM) C509044TGFB3 protein, humanOne source NLM
- UNII (FDA) 2Q1GS25JWNAVOTERMINConfirmed FDA, NLM
- RxNorm 1427086One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509044 | TGFB3 protein, human | One source NLM |
| UNII (FDA) | 2Q1GS25JWN | AVOTERMIN | Confirmed FDA, NLM |
| RxNorm | 1427086 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.